Goodwin Biotechnology, Inc. (GBI) was awarded a sub-contract from Emergent BioSolutions to conduct an early stage proof-of-concept feasibility process development to concentrate AVA filtrate for storage before the downstream process for BioThrax (Anthrax Vaccine Adsorbed). BioThrax is the only vaccine licensed by the FDA for the protection against anthrax disease.    “We’re excited about the opportunity to contribute our protein purification as well as processing experience and exper...